38 Week Extension Study to CAIN457C2303
| Status: | Terminated |
|---|---|
| Conditions: | Cervical Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 4/21/2016 |
| Start Date: | March 2010 |
| End Date: | January 2011 |
A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study)
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled
study to assess the difference in the rate of recurrent exacerbations in Behçet's patients
with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care
immunosuppressive therapy
study to assess the difference in the rate of recurrent exacerbations in Behçet's patients
with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care
immunosuppressive therapy
Inclusion Criteria:
Exclusion Criteria:
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials